220 related articles for article (PubMed ID: 26272032)
1. Structure-activity studies of Wnt/β-catenin inhibition in the Niclosamide chemotype: Identification of derivatives with improved drug exposure.
Mook RA; Wang J; Ren XR; Chen M; Spasojevic I; Barak LS; Lyerly HK; Chen W
Bioorg Med Chem; 2015 Sep; 23(17):5829-38. PubMed ID: 26272032
[TBL] [Abstract][Full Text] [Related]
2. Identification of DK419, a potent inhibitor of Wnt/β-catenin signaling and colorectal cancer growth.
Wang J; Mook RA; Ren XR; Zhang Q; Jing G; Lu M; Spasojevic I; Lyerly HK; Hsu D; Chen W
Bioorg Med Chem; 2018 Nov; 26(20):5435-5442. PubMed ID: 30274939
[TBL] [Abstract][Full Text] [Related]
3. Benzimidazole inhibitors from the Niclosamide chemotype inhibit Wnt/β-catenin signaling with selectivity over effects on ATP homeostasis.
Mook RA; Ren XR; Wang J; Piao H; Barak LS; Kim Lyerly H; Chen W
Bioorg Med Chem; 2017 Mar; 25(6):1804-1816. PubMed ID: 28233680
[TBL] [Abstract][Full Text] [Related]
4. Identification of novel triazole inhibitors of Wnt/β-catenin signaling based on the Niclosamide chemotype.
Mook RA; Wang J; Ren XR; Piao H; Lyerly HK; Chen W
Bioorg Med Chem Lett; 2019 Jan; 29(2):317-321. PubMed ID: 30551901
[TBL] [Abstract][Full Text] [Related]
5. Small molecule modulators of Wnt/β-catenin signaling.
Mook RA; Chen M; Lu J; Barak LS; Lyerly HK; Chen W
Bioorg Med Chem Lett; 2013 Apr; 23(7):2187-91. PubMed ID: 23453073
[TBL] [Abstract][Full Text] [Related]
6. The anthelmintic niclosamide inhibits colorectal cancer cell lines via modulation of the canonical and noncanonical Wnt signaling pathway.
Monin MB; Krause P; Stelling R; Bocuk D; Niebert S; Klemm F; Pukrop T; Koenig S
J Surg Res; 2016 Jun; 203(1):193-205. PubMed ID: 27338550
[TBL] [Abstract][Full Text] [Related]
7. Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/β-catenin pathway.
Lu W; Lin C; Roberts MJ; Waud WR; Piazza GA; Li Y
PLoS One; 2011; 6(12):e29290. PubMed ID: 22195040
[TBL] [Abstract][Full Text] [Related]
8. Niclosamide sensitizes triple-negative breast cancer cells to ionizing radiation in association with the inhibition of Wnt/β-catenin signaling.
Yin L; Gao Y; Zhang X; Wang J; Ding D; Zhang Y; Zhang J; Chen H
Oncotarget; 2016 Jul; 7(27):42126-42138. PubMed ID: 27363012
[TBL] [Abstract][Full Text] [Related]
9. Niclosamide-induced Wnt signaling inhibition in colorectal cancer is mediated by autophagy.
Wang J; Ren XR; Piao H; Zhao S; Osada T; Premont RT; Mook RA; Morse MA; Lyerly HK; Chen W
Biochem J; 2019 Feb; 476(3):535-546. PubMed ID: 30635359
[TBL] [Abstract][Full Text] [Related]
10. Niclosamide-conjugated polypeptide nanoparticles inhibit Wnt signaling and colon cancer growth.
Bhattacharyya J; Ren XR; Mook RA; Wang J; Spasojevic I; Premont RT; Li X; Chilkoti A; Chen W
Nanoscale; 2017 Aug; 9(34):12709-12717. PubMed ID: 28828438
[TBL] [Abstract][Full Text] [Related]
11. Targeting Wnt/β-catenin by anthelmintic drug niclosamide overcomes paclitaxel resistance in esophageal cancer.
Wei W; Liu H; Yuan J; Yao Y
Fundam Clin Pharmacol; 2021 Feb; 35(1):165-173. PubMed ID: 32579788
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of canonical WNT signaling attenuates human leiomyoma cell growth.
Ono M; Yin P; Navarro A; Moravek MB; Coon V JS; Druschitz SA; Gottardi CJ; Bulun SE
Fertil Steril; 2014 May; 101(5):1441-9. PubMed ID: 24534281
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy of niclosamide with gemcitabine inhibited cell proliferation and apoptosis via Wnt/β-catenin/c-Myc signaling pathway by inducing β-catenin ubiquitination in pancreatic cancer.
Kang HW; Kim JH; Lee DE; Lee YS; Kim MJ; Kim HS; Fang S; Lee BE; Lee KJ; Yoo J; Kim HJ; Park JS
Cancer Biol Ther; 2023 Dec; 24(1):2272334. PubMed ID: 37917550
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer.
Arend RC; Londoño-Joshi AI; Samant RS; Li Y; Conner M; Hidalgo B; Alvarez RD; Landen CN; Straughn JM; Buchsbaum DJ
Gynecol Oncol; 2014 Jul; 134(1):112-20. PubMed ID: 24736023
[TBL] [Abstract][Full Text] [Related]
15. Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations.
Osada T; Chen M; Yang XY; Spasojevic I; Vandeusen JB; Hsu D; Clary BM; Clay TM; Chen W; Morse MA; Lyerly HK
Cancer Res; 2011 Jun; 71(12):4172-82. PubMed ID: 21531761
[TBL] [Abstract][Full Text] [Related]
16. Niclosamide-loaded polymeric micelles ameliorate hepatocellular carcinoma in vivo through targeting Wnt and Notch pathways.
Zeyada MS; Abdel-Rahman N; El-Karef A; Yahia S; El-Sherbiny IM; Eissa LA
Life Sci; 2020 Nov; 261():118458. PubMed ID: 32961231
[TBL] [Abstract][Full Text] [Related]
17. SRI36160 is a specific inhibitor of Wnt/β-catenin signaling in human pancreatic and colorectal cancer cells.
Li Y; Oliver PG; Lu W; Pathak V; Sridharan S; Augelli-Szafran CE; Buchsbaum DJ; Suto MJ
Cancer Lett; 2017 Mar; 389():41-48. PubMed ID: 28043913
[TBL] [Abstract][Full Text] [Related]
18. Niclosamide, a Drug with Many (Re)purposes.
Kadri H; Lambourne OA; Mehellou Y
ChemMedChem; 2018 Jun; 13(11):1088-1091. PubMed ID: 29603892
[TBL] [Abstract][Full Text] [Related]
19. Bisleuconothine A, a bisindole alkaloid, inhibits colorectal cancer cell in vitro and in vivo targeting Wnt signaling.
Kong LM; Feng T; Wang YY; Li XY; Ye ZN; An T; Qing C; Luo XD; Li Y
Oncotarget; 2016 Mar; 7(9):10203-14. PubMed ID: 26862734
[TBL] [Abstract][Full Text] [Related]
20. The anti-helminthic niclosamide inhibits Wnt/Frizzled1 signaling.
Chen M; Wang J; Lu J; Bond MC; Ren XR; Lyerly HK; Barak LS; Chen W
Biochemistry; 2009 Nov; 48(43):10267-74. PubMed ID: 19772353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
